Alternatives to Tubulis

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Pioneering next-generation bispecific ADCs for cancer treatment.

Clinical-stage biopharma developing precisely designed cancer therapeutics using a proprietary cell-free protein synthesis platform.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Global immunology company developing antibody-based therapies for severe autoimmune diseases.

Developing engineered biologics to harness the immune system for disease treatment.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing novel therapeutics targeting dysfunctional DNA packaging for diseases like cancer.

Precision oncology company developing cancer therapies guided by proprietary functional genomics.

A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

Pioneering precision microbiome therapeutics for oncology using CRISPR and synthetic biology.

A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.

Developing a novel small molecule inhibitor for ovarian cancer treatment targeting DIO3.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers.

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.